SAO PAULO, (Reuters) - A coronavirus vaccine developed by China’s Sinovac Biotech was just 50.4% effective at preventing symptomatic infections in a Brazilian trial, researchers said yesterday, barely enough for regulatory approval and well below the rate announced last week.
The article New Brazil data shows disappointing 50.4% efficacy for China’s CoronaVac vaccine appeared first on Stabroek News.
